Asha Rani1, Purnima2, Anu Saini3, Vandana Dahiya4, Nehha Kasturiaa5, Manoj Kumar Yadav6, Archana Gupta7, Anjali Priyadarshini8, Arpana Vibhuti9, V. Samuel Raj10, Ramendra Pati Pandey
2PhD Students, Centre for Drug Design Discovery and Development, 3,4,6Assistant Professor, Department of Biomedical Engineering, 5Assistant Professor, Department of Biotechnology, 7,8Assistant Professor, Department of Microbiology, 9Associate Professor, Department of Biotechnology, 10Professor, Department of Biotechnology& Microbiology, 11Assistant Professor, Department of Biotechnology & Microbiology, SRM University, Sonipat, Haryana 131029, India.
|
AbstractCandida auris has developed as a multidrug-resistant (MDR) fungal pathogen connected to medical care around the world. Due to its outbreak potential, antibiotic resistance, and high mortality, Candida auris infection has arisen as a significant problem in the care of patients admitted to ICUs in India. Candidemia caused by C. auris has been recorded from three continents since the initial report of earcanal infection by this yeast in Japan in 2009, with a substantial number of cases from India. Some C. auris strains have higher minimum inhibitory concentrations (MICs) than amphotericin B and echinocandin compounds, while some C. auris strains are resistant to all antifungal medication classes. According to a comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Clinical and Laboratory Standards Institute (CLSI) techniques, C. auris isolates exhibit strikingly comparable fluconazole resistance but a broad range of MICs for the other antifungal drug classes. The goal of this research is to learn more about curcumin's antifungal properties. This polyphenolic chemical has been used for medical, culinary, and other uses throughout Asia for centuries. Although curcumin has been shown to have antifungal properties, a current study reveals that curcumin works by disrupting the fungal cell wall.
|